NeuroBo Pharmaceuticals, Inc. NRBO
Set alert
Day range unavailable
52-week range unavailable
- Open
- —
- Prev close
- 0.00
- Mkt cap
- 20.33M
- Vol
- 0
- Avg vol
- 0
- EPS
- 0.00
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- —
- High
- —
- Forward P/E
- -1.39
- Beta
- -0.28
- Short ratio
- 0.87
- Inst. own
- 12.71%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Nov 7, 2024
- 50-d avg
- 2.59
- 200-d avg
- 3.63
- 1y target
- 26.67
Key statistics
- Market cap
- 20.33M
- Enterprise value
- 437.95K
- Trailing P/E
- 0.00
- Forward P/E
- -1.39
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 1.57
- EPS (TTM)
- -4.29
- Beta
- -0.28
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 0
- Revenue growth
- 0.00%
- Free cash flow
- 0
- Total cash
- 21.67M
- Total debt
- 154.00K
- Return on equity
- -160.76%
- Shares outstanding
- 8.62M
- Short % of float
- 1.06%
- 50-day average
- 2.59
- 200-day average
- 3.63
Analyst view
Consensus: strong buy
- Target (low)
- 10.00
- Target (mean)
- 26.67
- Target (high)
- 48.00
- Strong buy1
- Buy1
- Hold0
- Sell0
- Strong sell0
Next earnings
Nov 7, 2024
Expected Nov 7, 2024. Consensus EPS estimate 0.00.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 7, 2024 | Sep 1, 2024 | -0.82 | — | — | — |
| Aug 14, 2024 | Jun 1, 2024 | -1.38 | — | — | — |
| May 9, 2024 | Mar 1, 2024 | -0.95 | — | — | — |
| Apr 4, 2024 | Dec 1, 2023 | -0.73 | — | — | — |
| Nov 13, 2023 | Sep 1, 2023 | 0.00 | — | — | — |
| Aug 9, 2023 | Jun 1, 2023 | 0.00 | — | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| May 8, 2024 | Maxim Group | init | — | Buy |
About NeuroBo Pharmaceuticals, Inc.
MetaVia Inc., a clinical-stage biotechnology company focuses on developing and commercializing novel pharmaceuticals to treat cardiometabolic diseases. It develops DA-1241, a novel G-Protein-Coupled Receptor 119 agonist with development optionality as a standalone and/or combination therapy that is in Phase 2a clinical trial for metabolic dysfunction-associated steatohepatitis (MASH), and has completed Phase 1 clinical trial for the treatment of type 2 diabetes mellitus (T2DM); and DA-1726, a novel oxyntomodulin analogue functioning as a GLP-1 receptor and glucagon receptor dual agonist, which is in preclinical development for the treatment of obesity. The company's therapeutic programs include ANA001, a proprietary oral niclosamide formulation for the treatment of patients with moderate COVID-19; NB-01 for the treatment of painful diabetic neuropathy; NB-02 for the treatment of cognitive impairment; and Gemcabene for the treatment of dyslipidemia. It has a license agreement with Pfizer Inc. for the research, development, manufacture, and commercialization of Gemcabene; and joint research agreement with Dong-A ST and ImmunoForge for the development of DA-1726. The company was formerly known as NeuroBo Pharmaceuticals, Inc. and changed its name to MetaVia Inc. in November 2024. MetaVia Inc. is headquartered in Cambridge, Massachusetts.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- metaviatx.com
News
- NeuroBo Pharmaceuticals Announces Strategic Realignment Ahead of Important Clinical Milestones with Name Change to MetaVia - Reflecting the Company's Focus on Cardiometabolic Diseases
- NeuroBo Pharmaceuticals to Participate in Investor Conferences in November
- NeuroBo Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Corporate Update
- NeuroBo Pharmaceuticals Completes Last Patient Last Visit in Its Phase 2a Clinical Trial Evaluating DA-1241 for the Treatment of MASH
- NeuroBo Pharmaceuticals to Participate in Investor Conferences in October
- NeuroBo Pharmaceuticals Announces Positive Top-Line Data From the SAD Part 1 of Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of Obesity
- NeuroBo to Participate in the H.C. Wainwright 26th Annual Global Investment Conference
- NeuroBo Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Corporate Update
- NeuroBo Pharmaceuticals Completes Enrollment of the SAD Part 1 of Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of Obesity
- NeuroBo Pharmaceuticals Announces Joint Research Agreement, Together with Dong-A ST and ImmunoForge to Develop a Long-Acting Once-Monthly Formulation of DA-1726 for the Treatment of Obesity
Your note
Sign in to keep a note on NRBO — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| DONG-A ST CO., LTD. | Beneficial Owner of more than 10% of a Class of Security | Sale | Sep 11, 2024 | 5,347,790 |
| GLICKMAN MARK A | Director | Stock Award(Grant) | Jun 6, 2024 | 9,740 |
| GROVES JASON L | Director | Stock Award(Grant) | Jun 6, 2024 | 17,552 |
| KIM HYUNG HEON | Chief Executive Officer | Stock Award(Grant) | Aug 10, 2023 | 625,064 |
| KIM NA YEON | Director and Beneficial Owner of more than 10% of a Class of Security | Stock Award(Grant) | Jul 26, 2023 | 302,013 |
| KOVEN ANDREW IAN | Director | Stock Award(Grant) | Jun 6, 2024 | 17,552 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Armistice Capital, LLC | 9.84% | 848,000 | 2.00M | Sep 29, 2024 |
| Affinity Asset Advisors, Llc | 1.04% | 89,222 | 210.56K | Sep 29, 2024 |
| Vanguard Group Inc | 0.70% | 60,452 | 142.67K | Sep 29, 2024 |
| Geode Capital Management, LLC | 0.38% | 32,574 | 76.87K | Sep 29, 2024 |
| Ferguson Wellman Capital Management, Inc. | 0.18% | 15,670 | 36.98K | Sep 29, 2024 |
| State Street Corporation | 0.18% | 15,633 | 36.89K | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Extended Market Index Fund | 0.33% | 28,020 | 66.13K | Jun 29, 2024 |
| Fidelity Extended Market Index Fund | 0.23% | 20,008 | 47.22K | Sep 29, 2024 |
| Vanguard Total Stock Market Index Fund | 0.22% | 19,328 | 45.61K | Jun 29, 2024 |
| Fidelity NASDAQ Composite Index Fund | 0.06% | 4,864 | 11.48K | Sep 29, 2024 |
| Fidelity Series Total Market Index Fund | 0.05% | 4,667 | 11.01K | Sep 29, 2024 |
| DFA U.S. Small Cap Series | 0.00% | 355 | 837 | Jul 30, 2024 |